Pfizer Inc. (NYSE: PFE) Develops Antiviral Pill That Could Lower Demand for COVID-19 Vaccines

Pfizer Inc. (NYSE: PFE) announced that it had developed an antivirus pill causing the stocks of vaccine producers in Asia to fall. The antivirus pill known as Pexlovid is 89% effective in decreasing the risk of hospitalization or death from COVID-19

Shares for the Chinese vaccine maker, Cansino Biologics Inc (OTCMKTS: CASBF), dropped by 17% in Hong Kong by Monday’s closing bell. The company’s investors seem to believe that the introduction of highly effective treatment options may decrease the global demand for the COVID-19 vaccines. However, doctors caution that while the antiviral pills give more treatment options should be considered as supplements rather than alternatives.

Dr. Stephen Griffin, an associate professor in the school of Medicine at the University of Leeds, shared her sentiments about the development stating that the pills will allow healthcare workers to prevent severe cases of COVID-19.

The Rumors on Albert Bourla

There is a lot of scrutiny facing pharmaceutical companies that develop COVID-19 vaccines as people grapple with whether they are safe. Rumors have followed these companies as they produce new vaccines, with some making some outrageous unverifiable claims. The latest unfounded claims have fallen on Pfizer.

Recently, a Canadian-based website wrote a Bearer Exclusive alleging that the CEO of Pfizer Albert Bourla was in jail following an investigation by the (FBI) Federal Bureau of Investigation for fraud. The piece stated that Bourla faces fraud charges for his role in deceiving customers of the drug’s effectiveness.

The report also alleged that the CEO was also on the hook for falsifying data and paying out large bribes. The publishers claim that it got the tip from an FBI agent who said that the CEO lied about the effectiveness of the vaccines and misled the customers on the side effects of the pill.

Pfizer would have to produce more vaccines as infections rise

A publication done by the Bloomberg Daybreak in Europe observed that the company’s ability to make 50 million vaccines by the end of the year was a significant breakthrough in the fight against COVID-19. However, the publication highlighted the rate at which the infection was rising and asked the company to find a way to develop more vaccines.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact ir@edm.media.

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@wallstreetpr.com) or his Google+ page (https://plus.google.com/u/0/116608759701551457422).